Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
#Technetium-99m Market Growth Potential: How Will Market Size Shift Through 2030?#_x000D_
The technetium-99m market has experienced significant expansion over the past few years. Projections indicate it will increase from $4.75 billion in 2025 to $4.99 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.1%. The market’s historical expansion is largely due to factors such as the restricted supply of radiopharmaceuticals, an increase in cardiovascular disease cases, enhancements in nuclear medicine facilities, governmental healthcare programs, and innovations in imaging technology._x000D_
_x000D_
The technetium-99m market size is projected to experience consistent expansion over the coming years. This market is anticipated to reach $6.01 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.8%. Factors contributing to this growth include a rising need for precise diagnostic tools, the broadening of hospital and imaging center networks, the creation of new Tc-99m radiopharmaceuticals, the incorporation of AI into nuclear imaging, and heightened awareness regarding early disease detection. Key trends identified for the forecast period encompass a greater uptake of SPECT imaging, an increase in cardiac and oncology diagnostic procedures, a demand for radiopharmaceuticals with short half-lives, the expansion of centralized radiopharmacy services, and improved regulatory adherence and safety protocols._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Technetium-99m Market Growth Backed By Core Demand Fundamentals#_x000D_
The technetium-99m market is expected to experience growth driven by the rising need for diagnostic imaging procedures. These medical techniques are utilized to generate visual representations of the body’s interior, assisting healthcare professionals in diagnosing and occasionally directing treatment for various health issues. The heightened demand for diagnostic imaging procedures is a consequence of the increasing prevalence of chronic diseases that require early and accurate detection. Technetium-99m facilitates diagnostic imaging procedures by enabling doctors to visualize the function of organs and tissues with great precision, leveraging its radioactive attributes to produce detailed images during nuclear medicine scans. For example, in November 2023, according to the National Health Service (NHS) England, a UK-based government department, 45.0 million imaging tests were performed in England in the year leading up to March 2023, signifying a 2.2% increase from the 44.0 million tests conducted in the previous year. Thus, the escalating demand for diagnostic imaging procedures is propelling the expansion of the technetium-99m market._x000D_
_x000D_
#Technetium-99m Market Segmentation: How Does The Market Break Down By Category?#_x000D_
The technetium-99m market covered in this report is segmented – _x000D_
_x000D_
1) By Product Type: Radiopharmaceuticals, Diagnostic Kits, Generators_x000D_
2) By Formulation Type: Liquid, Solid, Freeze-Dried_x000D_
3) By Application: Single Photon Emission Computed Tomography (SPECT) Imaging, Oncology, Cardiology, Neurology, Other Applications_x000D_
4) By End-User: Hospitals, Diagnostic Imaging Centers, Research Laboratories, Specialized Clinics, Other End-Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Radiopharmaceuticals: Sestamibi, Tetrofosmin, Sulfur Colloid, MAA (Macroaggregated Albumin), DTPA (Diethylenetriaminepentaacetic Acid)_x000D_
2) By Diagnostic Kits: Cardiac Imaging Kits, Bone Imaging Kits, Renal Imaging Kits, Hepatobiliary Imaging Kits, Pulmonary Imaging Kits_x000D_
3) By Generators: Hospital-Based Generators, Centralized Radiopharmacy Generators_x000D_
_x000D_
#Technetium-99m Market Growth Trends Reshaping The Competitive Landscape#_x000D_
Leading companies within the technetium-99m market are concentrating on developing innovative solutions, such as sophisticated radiopharmaceutical imaging agents, to improve the precision and availability of diagnostic imaging procedures for complex medical conditions. These advanced agents are specialized compounds containing radioactive labels that enable medical professionals to visualize internal body structures via imaging methods. For instance, in June 2024, Serac Healthcare Limited, a UK-based clinical radiopharmaceutical firm, secured Fast Track Designation from the US Food and Drug Administration (FDA) for 99mTc-maraciclatide, its novel single-photon emission computed tomography (SPECT)-computed tomography (CT) imaging agent. This agent is designed for visualizing and diagnosing superficial peritoneal endometriosis in women aged 16 years and older. As a technetium-99m-labeled targeted peptide imaging agent, 99mTc-maraciclatide specifically attaches to integrins overexpressed in endometriosis lesions, thus allowing for distinct visualization of affected areas during SPECT-CT scans. It presents a non-invasive diagnostic alternative to laparoscopic procedures, offering women with suspected endometriosis a safer and more accessible route to diagnosis. This agent utilizes the advantageous imaging characteristics of technetium-99m, including its ideal half-life and gamma emission energy, to produce high-quality diagnostic images with reduced patient radiation exposure. This development is set to enhance diagnostic precision and simplify treatment choices for endometriosis, simultaneously broadening the clinical utility of technetium-99m-based imaging within women’s health._x000D_
_x000D_
#Technetium-99m Market Competitive Landscape: Who Leads The Industry?#_x000D_
Major companies operating in the technetium-99m market are Cardinal Health Inc, GE Healthcare Technologies Inc, BWX Technologies Inc, Bracco Imaging S p A, Lantheus Holdings Inc, China Isotope And Radiation Corporation, Jubilant Pharma Limited, Curium Pharma LLC, Eckert And Ziegler Strahlen, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Isotopia Molecular Imaging Ltd, Cyclopharm Limited, SHINE Technologies LLC, Medi Radiopharma Kft, SDS Lifesciences Pvt Ltd, ANSTO Nuclear Medicine, IRE ELiT, Sam Young Unitech Co Ltd, RadioMedix Inc, Institute Of Isotopes Co Ltd, Monrol Nuclear Products _x000D_
_x000D_
#View The Full Technetium-99m Market Report:#_x000D_
_x000D_
#Technetium-99m Market Geographic Landscape: Which Region Dominates Industry Growth?#_x000D_
North America was the largest region in the technetium-99m market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the technetium-99m market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.